DanCann Pharma A/S: The first repackaging process has been completed at the new CannGros ApS facilities in Ansager
COPENHAGEN, Denmark, 24 February 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announces that The Company has successfully completed its first repackaging process at its new facilities in Ansager, where its subsidiary, CannGros ApS ("CannGros"), obtained approval for its facilities at the end of 2022.
The past few months have been dedicated to preparing for our first production, including the establishment of a quality management system (QMS) and training of personal in standard operating procedures (SOPs) and associated packaging procedures, similarly, the handling of the law under the Danish Pilot Programme for medical cannabis for the process and the handling of narcotic substances.
Louise Conradsen, CEO of CannGros, commented:
"The first products will be delivered to the wholesalers in week 10, respectively Nomeco and TMJ (Tjellesen Max Jenne), which will be a major milestone for our newly approved facility. A close and successful collaboration with wholesalers and doctors has ensured supply continuity for patients during the transition from Glostrup to Ansager, which is highly valued by the company."
“We would like to thank our partners for their collaboration prior to and following the repackaging process, including Eurographic, BHS, Nomeco, and TMJ. We are excited to send the products out to patients after successfully completing our first repackaging process, and we look forward to preparing and delivering even more products to patients from Ansager in the future. We are pleased to be able to make a difference for patients in Denmark.”
In week 8 and 9, CannGros will be packaging the first two orders at its new location in Ansager. Initially, 1,000 units have been repackaged, based on the three products ®, Bedica®, and Bediol®, and a total of approximately 2,000 units are expected to be repackaged in this first process.
About CannGros
CannGros ApS is approved for the production of cannabis products for medical use, in accordance with the law on the Danish Pilot Programme for medical cannabis. CannGros currently has three products (dried flowers and granules) included on the Danish Medicines Agency's list of medical cannabis products under the Danish Pilot Programme for medical cannabis, with import and distribution of the products Bedrocan®, Bedica®, and Bediol® to all the country's pharmacies.
For further information, please contact:
Louise Conradsen, CEO of CannGros,
Phone: +45 5384 6353
E-mail: [email protected]
About DanCann Pharma
DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company.
The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.
DanCann Pharma is EU-GMP-approved by the Danish Medicines Agency under the Danish Pilot Programme for medical cannabis, and have, among other things, license for manufacturing, export, import and distribution. The DanCann Pharma group also owns the subsidiary CannGros ApS, which is the market leader in Denmark with the import and distribution of the products Bedrocan®, Bedica® and Bediol® to all the Danish pharmacies.
DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm and sidelisted on OTCQB Venture Market in USA (OTCQB: DCPXF).
For more information, visit: www.dancann.com
For further information, please contact:
Jeppe Krog Rasmussen, CEO
E-mail: [email protected]
Forward-looking-statement:
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
